Om

Ocumension Therapeutics is a China-based ophthalmic pharmaceutical platform company focused on discovering, developing, and commercializing eye-care therapies. The company concentrates on both anterior and posterior segment diseases, addressing conditions such as glaucoma, ocular hypertension, myopia progression in children, and inflammatory eye disorders. Its portfolio combines in-licensed and internally developed products and candidates, including therapies like OT-401 (YUTIQ), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-301 (NCX 470), OT-101 and OT-202. Ocumension Therapeutics builds its pipeline through research and development capabilities and strategic collaborations with global partners, holding exclusive rights in Greater China for certain innovative ophthalmic compounds. Headquartered in Suzhou, China, the company operates primarily in the domestic market, supplying prescription ophthalmic medicines to ophthalmologists, hospitals, and specialized clinics. It positions itself as a specialized player within the pharmaceutical sector, aiming to provide a broad treatment portfolio across major ophthalmic indications in China.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I OCUMENSION THERAPEUTICS MED ENDAVU: Køb Ocumension Therapeutics ($5DG) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Ocumension Therapeutics, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.